Eligible AACR 2019 Annual Meeting Registrants – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 40
Molecular Correlates of Response to EGFR Inhibitors
Daniel A. Haber, M.D., Ph.D.
Massachusetts General Hospital Cancer Center, Charlestown, MA
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 12, 2006 8:00 PM-9:30 PM
Molecular Detection and Monitoring of Cancer Using Tumor-derived DNA in Plasma
Dr. Y. M. Dennis Lo
The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 12, 2006 8:00 PM-9:30 PM
Welcome from the AACR President
Geoffrey M. Wahl, Ph.D.
The Salk Institute for Biological Studies, La Jolla, CA
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 12, 2006 8:00 PM-9:30 PM
Case History: Lessons Learned from the MGMT Methylation Experience
Manel Esteller, M.D., Ph.D.
Spanish National Cancer Center, Madrid, Spain
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 8:00 AM-10:15 AM
Determinants for Response to Lapatinib – A Dual Inhibitor of ERBB1 and ERBB2
Tona Gilmer, Ph.D.
GlaxoSmithKline, Research Triangle Park, NC
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 8:00 AM-10:15 AM
Inhibition of erbB1/2 by small molecule tyrosine kinase inhibitors, but not trastuzumab, affects metabolic pathways: implications to cardiac toxicity.
Dr. Sarah S. Bacus
Targeted Molecular Diagnostics, Westmont, IL
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 8:00 AM-10:15 AM
Biomarkers of response to VEGF pathway-targeted therapy for renal cell carcinoma.
Dr. Erich B. Jaeger
University of California, San Francisco, CA
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 8:00 AM-10:15 AM
Overview
Judith S. Sebolt-Leopold, Ph.D.
Pfizer Global R&D, Ann Arbor, MI
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 10:35 AM-12:45 PM
Stem Cells, Mice and Men: Integrating Human and Mouse Genomics to Advance Understanding of the Biology and Treatment of Brain Tumors
Richard J. Gilbertson, M.D., Ph.D.
St. Jude Children's Research Center, Memphis, TN
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 10:35 AM-12:45 PM
In Vivo Platform for Drug Development and Biomarker Discovery in Pancreatic Cancer
Dr. Manuel Hidalgo
Johns Hopkins University School of Medicine, Baltimore, MD
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 10:35 AM-12:45 PM
Overview
Margaret R. Spitz, M.D.
UT M.D. Anderson Cancer Ctr., Houston, TX
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 4:15 PM-6:30 PM
Relevance of Cytochrome P450 Polymorphisms to Anticancer Drugs
William P. Petros, Pharm.D.
West Virginia University Health Sciences Center, Morgantown, WV
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 4:15 PM-6:30 PM
Individual Determinants of Vaccine Therapy
John J. Nemunaitis, M.D.
Mary Crowley Medical Research Center, Dallas, TX
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 4:15 PM-6:30 PM
Case History: The First Drug-Specific FDA-Approved Pharmacogenetic Test: UGT1A1 Genotyping for Irinotecan
Mark J. Ratain, M.D.
University of Chicago, Chicago, IL
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 4:15 PM-6:30 PM
Genes contributing to etoposide-induced cytotoxicity
Dr. Rong S. Huang
University of Chicago, Chicago, IL
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 13, 2006 4:15 PM-6:30 PM
Parametric Diffusion and Perfusion MRI in Monitoring Therapy Response
Hadassa Degani, Ph.D.
Weizmann Institute of Science, Rehovot, Israel
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 8:00 AM-10:15 AM
Optical Molecular Imaging for in vivo Detection of Dysplasia
Rebecca Richards-Kortum, Ph.D.
Rice University, Houston, TX
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 8:00 AM-10:15 AM
Characterization of human circulating endothelial cells to monitor response to antitumor therapy in human clinical trials
Dr. Evelyn McKeegan
Abbott Laboratories, Abbott Park, IL
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 8:00 AM-10:15 AM
A novel biomarker to diagnose and monitor acute myelogenous leukemia
Dr. Michael S. Lebowitz
Panacea Pharmaceuticals, Inc., Gaithersburg, MD
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 8:00 AM-10:15 AM
Moderators:
Gordon B. Mills, M.D., Ph.D.
UT M.D. Anderson Cancer Ctr., Houston, TX
David R. Parkinson, M.D.
Biogen Idec, San Diego, CA
Panelists:
Dr. Keith A. Baggerly
UT M.D. Anderson Cancer Ctr., Houston, TX
Dr. Chris Meda
Roche Molecular Diagnostics, Pleasanton, CA
Dr. Steven Young
Multiple Myeloma Research Consortium, Norwalk, CT
Cheryl L. Marks, Ph.D.
National Cancer Institute, Bethesda, MD
Dr. Gary B. Gordon
Abbott Laboratories, Abbott Park, IL
Dr. Richard M. Simon
NIH-NCI-DCTD, Bethesda, MD
Sudhir Srivastava, Ph.D.
National Cancer Institute, Rockville, MD
Janet Woodcock, M.D.
Food and Drug Administration, Rockville, MD
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 10:30 AM-12:45 PM
Overview
David R. Parkinson, M.D.
Biogen Idec, San Diego, CA
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 10:30 AM-12:45 PM
The Critical Path Initiative: Goals of Molecular Diagnostics from FDA's Perspective
Janet Woodcock, M.D.
Food and Drug Administration, Rockville, MD
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 10:30 AM-12:45 PM
Pitfalls in Experimental Design and Data Analysis
Dr. Keith A. Baggerly
UT M. D. Anderson Cancer Center, Houston, TX
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 10:30 AM-12:45 PM
Moving from Correlative Studies to Predictive Medicine: How to Include Biomarkers in Clinical Trials
Dr. Richard M. Simon
National Cancer Institute, Bethesda, MD
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 10:30 AM-12:45 PM
Overview
David A. Mankoff, M.D., Ph.D.
University of Washington Medical Center, Seattle, WA
from 2006 Molecular Diagnostics in Cancer Therapeutic Development conference on September 14, 2006 4:15 PM-6:30 PM
<< first | < prev page: of 2 records per page: next > | last >>
pages: 1 2 presentations: 1 to 25 of 40